azathioprine has been researched along with Uveitis in 70 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Uveitis: Inflammation of part or all of the uvea, the middle (vascular) tunic of the eye, and commonly involving the other tunics (sclera and cornea, and the retina). (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect of infliximab on the frequency of uveitis attacks and the visual prognosis in male patients with Behçet's disease in whom uveitis was resistant to combination therapy with corticosteroids, azathioprine, and cyclosporine." | 9.11 | Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. ( Gül, A; Inanc, M; Kamali, S; Kasapoglu, E; Mudun, A; Tugal-Tutkun, I; Urgancioglu, M, 2005) |
| "to evaluate effectiveness and side effects of azathioprine (AZA) in corticosteroid resistant noninfectious uveitis (CRNIU)." | 7.81 | Azathioprine for glucocorticoid resistant noninfectious uveitis. ( Ammous, I; Errais, K; Khalfallah, N; Letaief, I; Mili-Boussen, I; Zhioua, R; Zitouni, M, 2015) |
| "To investigate the therapeutic value of azathioprine as monotherapy or combined with other immunosuppressive drugs for uveitis in patients with juvenile idiopathic arthritis (JIA)." | 7.77 | Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. ( Ganser, G; Goebel, JC; Heiligenhaus, A; Heinz, C; Michels, H; Roesel, M, 2011) |
| "Tacrolimus's efficacy for the treatment of uveitis is maintained long-term, and its cardiovascular risk profile is excellent." | 7.74 | Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. ( Dick, AD; Hogan, AC; Lee, RW; McAvoy, CE, 2007) |
| "Three weeks after starting AZA for the treatment of uveitis, the patient was admitted to our clinic with cholestasis and constitutional symptoms." | 5.51 | Severe cholestasis due to azathioprine in Behcet's disease. ( Gisi, K; Ispiroglu, M; Kantarceken, B; Sayar, H, 2019) |
| "To investigate the effect of infliximab on the frequency of uveitis attacks and the visual prognosis in male patients with Behçet's disease in whom uveitis was resistant to combination therapy with corticosteroids, azathioprine, and cyclosporine." | 5.11 | Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. ( Gül, A; Inanc, M; Kamali, S; Kasapoglu, E; Mudun, A; Tugal-Tutkun, I; Urgancioglu, M, 2005) |
| "A VKH disease patient, well controlled on azathioprine therapy, presented a uveitis relapse eleven days after the first vaccination for COVID-19." | 4.12 | Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination. ( Accorinti, M; Manni, P; Saturno, MC, 2022) |
| "An immunocompetent, 25-year-old gentleman with bilateral chronic uveitis presented to various uveitis clinics at different points of time with documented typical clinical features of Toxoplasma Chorioretinitis (Headlight in fog appearance), Behcet's Disease (Hypopyon with peripheral retinal vasculitis), and Presumed Ocular Tuberculosis (Granulomatous Intermediate Uveitis with positive Interferon-gamma release assay) and had been treated with anti-toxoplasma drugs, oral prednisolone, and immunomodulation with oral Mycophenolate/oral Azathioprine to no avail." | 3.96 | Isolated intraocular histiocytosis-A rarely reported entity masquerading clinically as uveitis. ( Dudani, AI; Moreker, MR; Patel, K; Sharma, TR; Smruti, BK, 2020) |
| "To report the results of IFNα2a therapy in patients with Behçet uveitis refractory to azathioprine-cyclosporine combination treatment." | 3.85 | Interferon Alpha-2a Therapy in Patients with Refractory Behçet Uveitis. ( Aktas, Z; Cubuk, MO; Gurelik, G; Hasanreisoglu, B; Hasanreisoglu, M; Ozdek, S, 2017) |
| "To investigate the therapeutic value of azathioprine as monotherapy or combined with other immunosuppressive drugs for uveitis in patients with juvenile idiopathic arthritis (JIA)." | 3.77 | Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. ( Ganser, G; Goebel, JC; Heiligenhaus, A; Heinz, C; Michels, H; Roesel, M, 2011) |
| "Azathioprine was moderately effective as a single corticosteroid-sparing immunosuppressive agent in terms of control of inflammation and corticosteroid-sparing benefits, but required several months to achieve treatment goals; it seems especially useful for patients with intermediate uveitis." | 3.75 | Azathioprine for ocular inflammatory diseases. ( Foster, CS; Jabs, DA; Kempen, JH; Levy-Clarke, GA; Liesegang, TL; Newcomb, CW; Nussenblatt, RB; Pasadhika, S; Pujari, SS; Rosenbaum, JT; Suhler, EB; Thorne, JE, 2009) |
| "Extrapolation from transplant, rheumatology, skin disease, and inflammatory bowel disease cohorts to the ocular inflammation setting suggest that: 1) alkylating agents increase hematologic malignancy risk and cyclophosphamide increases bladder cancer risk, but less so with < or =18 months' duration of therapy and hydration, respectively; 2) calcineurin inhibitors and azathioprine probably do not increase total cancer risk to a detectable degree, except perhaps some other risk factors (uncommon in ocular inflammation patients) might interact with the former to raise risk; 3) tumor necrosis factor (TNF) inhibitors may accelerate diagnosis of cancer in the first six to 12 months, but probably do not increase long-term cancer risk; and 4) changes in risk with methotrexate, mycophenolate mofetil, and daclizumab appear negligible, although nontransplant data are limited for the latter agents." | 3.74 | Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. ( Daniel, E; Foster, CS; Gangaputra, S; Helzlsouer, KJ; Jabs, DA; Kempen, JH; Levy-Clarke, GA; Nussenblatt, RB; Rosenbaum, JT; Suhler, EB; Thorne, JE, 2008) |
"Ability to control ocular inflammation and to taper prednisone to | 3.74 | Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. ( Dunn, JP; Galor, A; Jabs, DA; Kedhar, SR; Leder, HA; Peters, GB; Thorne, JE, 2008) | |
| "Tacrolimus's efficacy for the treatment of uveitis is maintained long-term, and its cardiovascular risk profile is excellent." | 3.74 | Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. ( Dick, AD; Hogan, AC; Lee, RW; McAvoy, CE, 2007) |
| "Twenty-five patients with severe, progressive, chronic uveitis who were poorly responsive or unresponsive to corticosteroid therapy received low-dose prednisone and cytotoxic immunosuppressive therapy." | 3.66 | Immunosuppressive therapy for severe chronic uveitis. ( Andrasch, RH; Burns, RP; Pirofsky, B, 1978) |
| "Azathioprine was superior to placebo in the prevention of new eye disease in group 1 (1 vs." | 2.67 | A controlled trial of azathioprine in Behçet's syndrome. ( Barnes, CG; Lovatt, GE; Oğuz, V; Ozyazgan, Y; Pazarli, H; Serdaroğlu, S; Silman, A; Tüzün, Y; Yazici, H; Yurdakul, S, 1990) |
| "Atypical Cogan's syndrome is more commonly associated with systemic manifestations than typical disease, and may be refractory to immunosuppressive treatment." | 2.45 | Cogan's syndrome: present and future directions. ( Harney, S; Molloy, M; Murphy, G; Shanahan, F; Sullivan, MO, 2009) |
| "Oral corticosteroids remain the main therapeutical choice in patients with uveitis not responding to topical treatment, however their chronic use can be very toxic, especially for bones (osteoporosis or growth retardation)." | 2.41 | [Treatment of uveitis with immunosuppressives: antimetabolites and alkylating agents]. ( Caspers-Velu, LE, 2001) |
| "To report the clinical profile of Behcet's disease and its management with immunosuppressants and biologics in a cohort of 25 patients from a tertiary eye care center in South India." | 1.91 | Clinical profile and management with immunosuppressants and biologics in Behcet's uveitis: A cohort of 25 patients from a tertiary eye care center in South India. ( Ahmed, AS; Biswas, J; Ramdoss, J; Singh, P, 2023) |
| "Three weeks after starting AZA for the treatment of uveitis, the patient was admitted to our clinic with cholestasis and constitutional symptoms." | 1.51 | Severe cholestasis due to azathioprine in Behcet's disease. ( Gisi, K; Ispiroglu, M; Kantarceken, B; Sayar, H, 2019) |
| "Sarcoidosis is a multisystem disease of unknown aetiology with pulmonary involvement in most patients." | 1.48 | Atypical sarcoidosis-associated uveitis: diagnostic challenges. ( Cehajic Kapetanovic, J; Jones, NP; Steeples, LR, 2018) |
| "We report a Chinese man with VKH syndrome presenting with multiple cranial nerve palsy and bilateral pan-uveitis, who developed disseminated high-grade B cell lymphoma after 3-year treatment with azathioprine." | 1.33 | High-grade lymphoma after azathioprine treatment for Vogt-Kaganayi-Harada syndrome. ( Au, WY; Ho, SL; Hon, C; Ma, ES; Trendell-Smith, NJ, 2005) |
| " The CSA-associated toxicity may be reduced by initiating therapy at very low initial doses, with incremental dosage escalation to the desired target range." | 1.29 | Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. ( Foster, CS; Rodriguez, A; Vitale, AT, 1996) |
| "Bilateral uveitis was the initial manifestation of a limited form of Wegener granulomatosis in a 47-year-old man." | 1.25 | Limited form of Wegener granulomatosis. Eye involvement as a major sign. ( Coutu, RE; Friedman, E; Klein, M; Lessell, S; Snider, GL, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (32.86) | 18.7374 |
| 1990's | 9 (12.86) | 18.2507 |
| 2000's | 17 (24.29) | 29.6817 |
| 2010's | 17 (24.29) | 24.3611 |
| 2020's | 4 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Accorinti, M | 1 |
| Saturno, MC | 1 |
| Manni, P | 1 |
| Ramdoss, J | 1 |
| Singh, P | 1 |
| Ahmed, AS | 1 |
| Biswas, J | 1 |
| Moreker, MR | 1 |
| Dudani, AI | 1 |
| Sharma, TR | 1 |
| Patel, K | 1 |
| Smruti, BK | 1 |
| Waszczyk-Łączak, M | 1 |
| Łazicka-Gałecka, M | 1 |
| Chomicz, L | 1 |
| Mucha, K | 1 |
| Pączek, L | 1 |
| Szaflik, JP | 1 |
| Markomichelakis, NN | 1 |
| Aissopou, EK | 1 |
| Maselos, S | 1 |
| Tugal-Tutkun, I | 3 |
| Sfikakis, PP | 1 |
| Cehajic Kapetanovic, J | 1 |
| Jones, NP | 2 |
| Steeples, LR | 1 |
| Rossi, DC | 1 |
| Ribi, C | 1 |
| Guex-Crosier, Y | 1 |
| Gisi, K | 1 |
| Ispiroglu, M | 1 |
| Kantarceken, B | 1 |
| Sayar, H | 1 |
| Lima, BR | 1 |
| Nussenblatt, RB | 3 |
| Sen, HN | 1 |
| Joshi, L | 1 |
| Talat, L | 1 |
| Yaganti, S | 1 |
| Sandhu, S | 1 |
| Taylor, SR | 1 |
| Wakefield, D | 1 |
| McCluskey, P | 1 |
| Lightman, S | 1 |
| Tanawade, RG | 1 |
| Tsierkezou, L | 1 |
| Bindra, MS | 1 |
| Patton, NA | 1 |
| Silva-Fernández, L | 1 |
| Pérez-Vicente, S | 1 |
| Martín-Martínez, MA | 1 |
| López-González, R | 1 |
| Liu, X | 1 |
| Zhang, M | 1 |
| Vitale, A | 1 |
| Rigante, D | 1 |
| Caso, F | 1 |
| Franceschini, R | 1 |
| Cantarini, L | 1 |
| Mili-Boussen, I | 1 |
| Zitouni, M | 1 |
| Ammous, I | 1 |
| Letaief, I | 1 |
| Errais, K | 1 |
| Zhioua, R | 1 |
| Khalfallah, N | 1 |
| Hasanreisoglu, M | 1 |
| Cubuk, MO | 1 |
| Ozdek, S | 1 |
| Gurelik, G | 1 |
| Aktas, Z | 1 |
| Hasanreisoglu, B | 1 |
| Jones, N | 1 |
| Kempen, JH | 2 |
| Gangaputra, S | 1 |
| Daniel, E | 1 |
| Levy-Clarke, GA | 2 |
| Rosenbaum, JT | 2 |
| Suhler, EB | 2 |
| Thorne, JE | 3 |
| Foster, CS | 4 |
| Jabs, DA | 3 |
| Helzlsouer, KJ | 1 |
| Galor, A | 1 |
| Leder, HA | 1 |
| Kedhar, SR | 1 |
| Dunn, JP | 1 |
| Peters, GB | 1 |
| Murphy, G | 1 |
| Sullivan, MO | 1 |
| Shanahan, F | 1 |
| Harney, S | 1 |
| Molloy, M | 1 |
| Angelucci, E | 1 |
| Cesarini, M | 1 |
| Vernia, P | 1 |
| Pasadhika, S | 1 |
| Newcomb, CW | 1 |
| Liesegang, TL | 1 |
| Pujari, SS | 1 |
| Karadeli, E | 1 |
| Ulu, EM | 1 |
| Pye, CC | 1 |
| Goebel, JC | 1 |
| Roesel, M | 1 |
| Heinz, C | 1 |
| Michels, H | 1 |
| Ganser, G | 1 |
| Heiligenhaus, A | 1 |
| Sreekantam, S | 1 |
| Denniston, AK | 1 |
| Murray, PI | 1 |
| Androudi, S | 1 |
| Brazitikos, P | 1 |
| Iaccheri, B | 1 |
| Fiore, T | 1 |
| Christen, W | 1 |
| Meniconi, M | 1 |
| Kohnen, EM | 1 |
| Pansdorf, Y | 1 |
| Zubcov, A | 1 |
| Mayo, JM | 1 |
| Colmenarejo, MB | 1 |
| Vaquerizo, PJ | 1 |
| Gutierrez, MV | 1 |
| Hon, C | 1 |
| Ho, SL | 1 |
| Ma, ES | 1 |
| Trendell-Smith, NJ | 1 |
| Au, WY | 1 |
| Mudun, A | 1 |
| Urgancioglu, M | 1 |
| Kamali, S | 1 |
| Kasapoglu, E | 1 |
| Inanc, M | 1 |
| Gül, A | 2 |
| Maíz, B | 1 |
| Odriozola, M | 1 |
| Blanco, A | 1 |
| Fernández, J | 1 |
| Castiella, A | 1 |
| Sigle, KJ | 1 |
| McLellan, GJ | 1 |
| Haynes, JS | 1 |
| Myers, RK | 1 |
| Betts, DM | 1 |
| Hogan, AC | 1 |
| McAvoy, CE | 1 |
| Dick, AD | 2 |
| Lee, RW | 1 |
| Kulaber, A | 1 |
| Yentür, SP | 1 |
| Akman-Demir, G | 1 |
| Kaneko, F | 1 |
| Saruhan-Direskeneli, G | 1 |
| Cuchacovich, M | 1 |
| Pacheco, P | 1 |
| Díaz, G | 1 |
| Rojas, B | 1 |
| Stoppel, J | 1 |
| Merino, G | 1 |
| Verdaguer, JI | 1 |
| Verdaguer, J | 1 |
| Villarroel, F | 1 |
| Gündüz, E | 1 |
| Korkmaz, C | 1 |
| Kaşifoğlu, T | 1 |
| Gülbaş, Z | 1 |
| Hornstein, OP | 1 |
| Djawari, D | 1 |
| Martenet, AC | 4 |
| Niessen, F | 1 |
| Campinchi, R | 1 |
| Bloch-Michel, E | 1 |
| Anglade, E | 1 |
| Whitcup, SM | 1 |
| Vitale, AT | 1 |
| Rodriguez, A | 1 |
| de la Serna Higuera, C | 1 |
| Moreira Vicente, VE | 1 |
| Sanz de Villalobos, E | 1 |
| Kilmartin, DJ | 1 |
| Forrester, JV | 1 |
| Van Gelder, RN | 1 |
| Kaplan, HJ | 1 |
| Grahn, BH | 1 |
| Cullen, CL | 1 |
| Wolfer, J | 1 |
| Caspers-Velu, LE | 1 |
| Andrasch, RH | 2 |
| Pirofsky, B | 2 |
| Burns, RP | 2 |
| James, DG | 1 |
| Friedmann, AI | 1 |
| Graham, E | 1 |
| Coutu, RE | 1 |
| Klein, M | 1 |
| Lessell, S | 1 |
| Friedman, E | 1 |
| Snider, GL | 1 |
| Sundmacher, R | 1 |
| Goldenstein-Schainberg, C | 1 |
| Pereira, RM | 1 |
| Gusukuma, MC | 1 |
| Messina, WC | 1 |
| Cossermelli, W | 1 |
| O'Duffy, JD | 1 |
| Yazici, H | 1 |
| Pazarli, H | 1 |
| Barnes, CG | 1 |
| Tüzün, Y | 1 |
| Ozyazgan, Y | 1 |
| Silman, A | 1 |
| Serdaroğlu, S | 1 |
| Oğuz, V | 1 |
| Yurdakul, S | 1 |
| Lovatt, GE | 1 |
| Dottan, S | 1 |
| Glerstein, S | 1 |
| Naveh, N | 1 |
| Smecka, Z | 1 |
| Smecková, M | 1 |
| Svec, V | 1 |
| Obrucníková, E | 1 |
| Pietruschka, G | 1 |
| Bonnet, M | 1 |
| Perkins, ES | 1 |
| Aronson, SB | 1 |
| Cerný, M | 1 |
| Newell, FW | 1 |
| Krill, AE | 1 |
| Thomann, H | 1 |
| Schumacher, K | 1 |
| Utermann, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial[NCT01829295] | Phase 3 | 216 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Controlled ocular inflammation (≤ 0.5+ anterior chamber cells, ≤ 0.5+ vitreous haze, no active retinal/choroidal lesions in both eyes) with 7.5 mg/day of oral prednisone and ≤ 2 drops/day of topical 1% prednisolone acetate for patients who crossed over to other medication following treatment failure at 6 months (or earlier). (NCT01829295)
Timeframe: 6 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Switched Over to Methotrexate | 20 |
| Switched Over to Mycophenolate Mofetil | 7 |
Controlled ocular inflammation (≤ 0.5+ anterior chamber cells, ≤ 0.5+ vitreous haze, no active retinal/choroidal lesions in both eyes) with 7.5 mg/day of oral prednisone and ≤ 2 drops/day of topical 1% prednisolone acetate in patients who were a treatment success at the primary outcome of 6 months. (NCT01829295)
Timeframe: 12 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methotrexate | 48 |
| Mycophenolate Mofetil | 40 |
Controlled ocular inflammation (≤ 0.5+ anterior chamber cells, ≤ 0.5+ vitreous haze, no active retinal/choroidal lesions in both eyes) with 7.5 mg/day of oral prednisone and ≤ 2 drops/day of topical 1% prednisolone acetate. (NCT01829295)
Timeframe: 6 Months
| Intervention | Participants (Count of Participants) |
|---|---|
| Methotrexate | 64 |
| Mycophenolate Mofetil | 56 |
12 reviews available for azathioprine and Uveitis
| Article | Year |
|---|---|
Treatment of chronic non-infectious uveitis and scleritis.
Topics: Adrenal Cortex Hormones; Azathioprine; Cyclosporine; Enzyme Inhibitors; Immunosuppressive Agents; Me | 2019 |
Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Anti-Inflammatory Agents; Antimetabolites; Azathioprine; | 2013 |
Cogan's syndrome: present and future directions.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Dose-Response Relationship, Drug; Fatal Outcome; Femal | 2009 |
[Non-infectious oral aphthous disorders. 2. Behçet's syndrome (malignant aphthosis)].
Topics: Adrenal Cortex Hormones; Azathioprine; Behcet Syndrome; Bone Diseases; Central Nervous System Diseas | 1980 |
[Therapy of endogenous uveitis. Immunosuppression].
Topics: Adult; Azathioprine; Child; Chlorambucil; Cyclophosphamide; Humans; Immunosuppressive Agents; Procar | 1980 |
The diagnosis and management of uveitis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Azathioprine; Clinical Trials as Topic; Cyclophosp | 1995 |
Immunosuppression in uveitis therapy.
Topics: Administration, Oral; Administration, Topical; Animals; Arrestin; Azathioprine; Chlorambucil; Cyclop | 1999 |
[Treatment of uveitis with immunosuppressives: antimetabolites and alkylating agents].
Topics: Adult; Aged; Antimetabolites; Antineoplastic Agents, Alkylating; Azathioprine; Child; Chlorambucil; | 2001 |
Cytotoxic drugs in treatment of nonmalignant diseases.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Azathioprine; Chlor | 1972 |
[Immunodepressors in ophthalmology].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Antibiotics, Antineoplastic; Antilymphocyte Se | 1971 |
Recent advances in the study of uveitis.
Topics: Adult; Antibodies; Antigen-Antibody Reactions; Aqueous Humor; Azathioprine; Cell Migration Inhibitio | 1974 |
The uvea.
Topics: Anaphylaxis; Animals; Azathioprine; Chlorambucil; Epidemiologic Methods; Humans; Methotrexate; Stero | 1969 |
4 trials available for azathioprine and Uveitis
| Article | Year |
|---|---|
Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Azathioprine; Behcet Syndrome; Cyclosporine; | 2005 |
[Role of Azathioprine in steroid resistant non infectious ocular inflammatory diseases].
Topics: Adolescent; Adult; Aged; Azathioprine; Choroid Diseases; Drug Resistance; Drug Therapy, Combination; | 2007 |
Behçet's syndrome.
Topics: Azathioprine; Behcet Syndrome; Clinical Trials as Topic; Eye Diseases; Humans; Suppuration; Uveitis | 1990 |
A controlled trial of azathioprine in Behçet's syndrome.
Topics: Adult; Azathioprine; Behcet Syndrome; Double-Blind Method; Eye Diseases; Humans; Male; Patient Compl | 1990 |
54 other studies available for azathioprine and Uveitis
| Article | Year |
|---|---|
Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Topics: Adrenal Cortex Hormones; Azathioprine; Chronic Disease; COVID-19; COVID-19 Vaccines; Female; Humans; | 2022 |
Clinical profile and management with immunosuppressants and biologics in Behcet's uveitis: A cohort of 25 patients from a tertiary eye care center in South India.
Topics: Adolescent; Adult; Azathioprine; Behcet Syndrome; Biological Products; Cyclosporins; Female; Humans; | 2023 |
Isolated intraocular histiocytosis-A rarely reported entity masquerading clinically as uveitis.
Topics: Adult; Azathioprine; Behcet Syndrome; Histiocytosis; Humans; Male; Retinal Vasculitis; Uveitis | 2020 |
The first investigation on differences in the effectiveness of mycophenolate mofetil and azathioprine antimetabolites determined in Polish patients treated for non-infectious uveitis.
Topics: Adult; Aged; Antimetabolites; Azathioprine; Female; Humans; Male; Middle Aged; Mycophenolic Acid; Po | 2020 |
Biologic Treatment Options for Retinal Neovascularization in Behçet's Disease.
Topics: Adalimumab; Administration, Oral; Antirheumatic Agents; Azathioprine; Behcet Syndrome; Child; Glucoc | 2019 |
Atypical sarcoidosis-associated uveitis: diagnostic challenges.
Topics: Adrenal Cortex Hormones; Azathioprine; Choroiditis; Diagnosis, Differential; Drug Administration Sch | 2018 |
Severe cholestasis due to azathioprine in Behcet's disease.
Topics: Adult; Azathioprine; Behcet Syndrome; Chemical and Drug Induced Liver Injury; Cholestasis; Humans; I | 2019 |
Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Cohort Studies; Cyclosporine; Drug S | 2014 |
Visual outcomes of pars plana vitrectomy with epiretinal membrane peel in patients with uveitis.
Topics: Adolescent; Adult; Aged; Azathioprine; Drug Therapy, Combination; Endotamponade; Epiretinal Membrane | 2015 |
Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain.
Topics: Adult; Antimalarials; Antirheumatic Agents; Azathioprine; Cohort Studies; Cyclophosphamide; Cyclospo | 2015 |
[Uveitic macular edema and the pharmacotherapy].
Topics: Acetazolamide; Adrenal Cortex Hormones; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; | 2015 |
Interleukin-1 blockade in neuro-Behçet's disease: a case-based reflection.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Behcet Syndrome; Dis | 2017 |
Azathioprine for glucocorticoid resistant noninfectious uveitis.
Topics: Adult; Azathioprine; Drug Resistance; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Mal | 2015 |
Interferon Alpha-2a Therapy in Patients with Refractory Behçet Uveitis.
Topics: Adolescent; Adult; Azathioprine; Behcet Syndrome; Child; Cyclosporine; Drug Combinations; Drug Resis | 2017 |
Sepsis During Immunosuppression for Sight-threatening Uveitis: The Flip side.
Topics: Adult; Aged; Azathioprine; Bacteremia; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immu | 2018 |
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Azathioprine; Daclizumab | 2008 |
Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites; Azathioprine; Child; Female; Glucocorti | 2008 |
Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressi
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, R | 2010 |
Azathioprine for ocular inflammatory diseases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Female; Follow-Up Studies; Humans; | 2009 |
Acute sarcoid myositis with unusual radiologic findings.
Topics: Anti-Inflammatory Agents; Azathioprine; Blood Sedimentation; C-Reactive Protein; Humans; Immunosuppr | 2010 |
Uveodermatologic syndrome in an Akita.
Topics: Animals; Azathioprine; Blindness; Dog Diseases; Dogs; Female; Pigmentation Disorders; Prednisolone; | 2009 |
Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis.
Topics: Adolescent; Arthritis, Juvenile; Azathioprine; Child; Child, Preschool; Female; Humans; Immunosuppre | 2011 |
Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema.
Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Azathioprine; Cataract; Cataract Extraction; | 2011 |
Outcomes of early and late immunomodulatory treatment in patients with HLA-B27-associated chronic uveitis.
Topics: Adult; Azathioprine; Chronic Disease; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Fem | 2003 |
[Recurrent uveitis with bilateral exudative retinal detachment. 10-year-old boy with bilaterally impaired vision and eye pain. Vogt-Koyanagi-Harada syndrome].
Topics: Azathioprine; Child; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2004 |
Hypersensitivity reaction to azathioprine in a patient with ulcerative colitis. Infrequent manifestations.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Diagnosis, Differential; Drug Hypersensitivity; Fever; Hum | 2004 |
High-grade lymphoma after azathioprine treatment for Vogt-Kaganayi-Harada syndrome.
Topics: Adult; Azathioprine; Carcinogens; Cranial Nerve Diseases; Humans; Immunophenotyping; Lymph Nodes; Ly | 2005 |
[Autoimmune hepatitis in a patient with uveitis].
Topics: Adrenal Cortex Hormones; Adult; Autoimmune Diseases; Azathioprine; Drug Therapy, Combination; Female | 2005 |
Unilateral uveitis in a dog with uveodermatologic syndrome.
Topics: Adrenal Cortex Hormones; Animals; Azathioprine; Carbonic Anhydrase Inhibitors; Diagnosis, Differenti | 2006 |
Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis.
Topics: Adolescent; Adult; Azathioprine; Child; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppr | 2007 |
Pro-inflammatory cellular immune response in Behçet's disease.
Topics: Adult; alpha-Crystallin B Chain; Antigens, Bacterial; Azathioprine; Behcet Syndrome; Cell Proliferat | 2007 |
Unusual presentation of non-Hodgkin lymphoma: polyarthritis and uveitis mimicking a rheumatologic disease.
Topics: Arthritis; Arthritis, Rheumatoid; Azathioprine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middl | 2008 |
[Value and complications of immunosuppressive therapy in uveitis of Behcet's disease or of other etiology. Apropos of 40 cases].
Topics: Adult; Aged; Azathioprine; Behcet Syndrome; Child; Chlorambucil; Drug Therapy, Combination; Female; | 1982 |
[Failures of cytostatic treatment in ophthalmology (author's transl)].
Topics: Adult; Azathioprine; Child; Corneal Diseases; Cyclophosphamide; Eye Diseases; Female; Humans; Immuno | 1980 |
Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Chronic Disease; Cyclosporine; Drug Therapy, Co | 1996 |
[Mixed hepatitis induced by azathioprine].
Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Female; Humans; Immunosuppressive Agent | 1996 |
Cyclosporin A therapy in refractory non-infectious childhood uveitis.
Topics: Adolescent; Arthritis, Juvenile; Azathioprine; Child; Child, Preschool; Chronic Disease; Cyclosporin | 1998 |
Diagnostic ophthalmology. Necrotic scleritis and uveitis.
Topics: Adrenal Cortex Hormones; Animals; Azathioprine; Dog Diseases; Dogs; Female; Immunosuppressive Agents | 1999 |
Immunosuppressive therapy for severe chronic uveitis.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Chlorambucil; Chronic Disease; Drug | 1978 |
Immunosuppressive therapy of severe chronic uveitis.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Chlorambucil; Female; Humans; Male; Prednisone; U | 1976 |
Uveitis. A series of 368 patients.
Topics: Adolescent; Adult; Aged; Antigen-Antibody Complex; Autoantibodies; Azathioprine; Child; Child, Presc | 1976 |
Limited form of Wegener granulomatosis. Eye involvement as a major sign.
Topics: Azathioprine; Biopsy; Blindness; Fundus Oculi; Granulomatosis with Polyangiitis; Humans; Lung; Male; | 1975 |
Editorial: Immunosuppressive treatment for uveitis.
Topics: Adrenal Cortex Hormones; Azathioprine; Chlorambucil; Humans; Immunosuppressive Agents; Methotrexate; | 1975 |
[Diagnosis of Vogt-Koyanagi-Harada-syndrome (uveoencephalitis) (author's transl)].
Topics: Adult; Azathioprine; Diagnosis, Differential; Female; Fundus Oculi; Germany, West; Glucocorticoids; | 1975 |
[Results of immunosuppression by cytostatics in ophthalmology].
Topics: Adult; Azathioprine; Behcet Syndrome; Cyclophosphamide; Evaluation Studies as Topic; Female; Humans; | 1976 |
Childhood linear scleroderma "en coup de sabre" with uveitis.
Topics: Autoantibodies; Azathioprine; Child; Diagnosis, Differential; Facial Hemiatrophy; Humans; Male; Peni | 1990 |
Azathioprine-induced in vitro inhibition of prostaglandin E2 production by rabbit retina.
Topics: Animals; Azathioprine; Dose-Response Relationship, Drug; In Vitro Techniques; Indomethacin; Prostagl | 1987 |
[Personal experience with cytostatic treatment of severe uveitis].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Child; Drug Therapy, Combination; Fe | 1986 |
[Contribution on the clinical problems of idiopathic panuveitis (author's transl)].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Azathioprine; Child; Child, Preschool; Chorioretinit | 1974 |
[Indications for immunosuppression by use of cytostatics in ophthalmology].
Topics: Adolescent; Adult; Aged; Autoimmune Diseases; Azathioprine; Child; Corneal Transplantation; Cyclopho | 1972 |
[Therapy of endogenous intraocular inflammation with azathioprine].
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Chronic Disease; Drug Synergism; Female; Humans; | 1971 |
Treatment of uveitis with azathioprine (Imuran).
Topics: Adolescent; Adult; Aged; Azathioprine; Chronic Disease; Female; Glucocorticoids; Histoplasmosis; Hum | 1967 |
[Observations on immunosuppressive therapy of chronic eye inflammations].
Topics: Adult; Azathioprine; Behcet Syndrome; Humans; Male; Prednisone; Prognosis; Uveitis | 1970 |
[The treatment of endogenous uveitis with antimetabolites].
Topics: Adult; Aged; Azathioprine; Choroiditis; Humans; Prednisone; Uveitis | 1970 |